GLP-1 Medications and Hair Loss: What the Research Shows
Hair loss affects many GLP-1 users. Learn what the science says about why it happens, who is most at risk, and evidence-based strategies to minimize shedding.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on April 10, 2026
Our medical review process ensures clinical accuracy and patient safety.
Hair loss is one of the most emotionally distressing side effects reported by people taking GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). While weight loss itself is the goal, an unexpected outcome for a significant number of users is noticeable thinning or shedding — often starting around three to six months into treatment.
Understanding what drives this phenomenon, who faces the greatest risk, and what can be done about it is increasingly important as GLP-1 prescriptions continue to surge worldwide.
Evidence: "Hair loss was reported more frequently in patients with greater weight loss (≥20% body weight), suggesting the events were potentially related to the magnitude of weight loss rather than a direct drug effect." — Burke JM, et al. J Am Acad Dermatol. 2025. DOI: 10.1016/j.jaad.2025.01.046
How Common Is Hair Loss on GLP-1 Medications?
Hair loss is not listed as a primary side effect in the FDA labeling for semaglutide or tirzepatide, but pharmacovigilance data and clinical studies paint a consistent picture: users of these drugs have a meaningfully elevated risk compared to the general population.
A retrospective cohort study published in the Journal of the American Academy of Dermatology analyzed electronic health records from a large U.S. database and found that patients on GLP-1 receptor agonists had significantly higher rates of alopecia diagnoses than matched controls. Tirzepatide was associated with a higher incidence of telogen effluvium compared to other weight-loss medications.
Evidence: "Increased risk of telogen effluvium with tirzepatide compared to other weight loss medications was observed in a retrospective cohort TriNetX database study." — Tran JT, et al. J Am Acad Dermatol. 2025. DOI: 10.1016/j.jaad.2025.02659
Disproportionality analyses from the FDA Adverse Event Reporting System (FAERS) further confirm the signal. Semaglutide was associated with an adjusted reporting odds ratio (aROR) of 2.46 (95% CI: 2.14–2.83) for alopecia, while tirzepatide showed an aROR of 1.73 (95% CI: 1.42–2.09) — both statistically significant.
Reported Rates Across Key Studies
| Medication | Type of Alopecia | Incidence / aROR | Source |
|---|---|---|---|
| Semaglutide | Telogen effluvium | aROR 2.46 | FAERS pharmacovigilance |
| Tirzepatide | Telogen effluvium | aROR 1.73 | FAERS pharmacovigilance |
| Semaglutide (≥20% weight loss) | Diffuse shedding | 5.3% of users | Burke et al., JAAD 2025 |
| Semaglutide (<20% weight loss) | Diffuse shedding | 2.5% of users | Burke et al., JAAD 2025 |
Why GLP-1 Medications Cause Hair Loss
The mechanism behind GLP-1-related hair loss is not yet fully understood, but three main pathways have been proposed.
1. Telogen Effluvium From Rapid Weight Loss
The most widely accepted explanation is telogen effluvium (TE) — a reactive form of diffuse hair shedding triggered by a physiological stressor. When the body undergoes rapid caloric restriction or sudden, significant weight loss, hair follicles can be pushed prematurely from the growth phase (anagen) into the shedding phase (telogen).
TE typically becomes clinically apparent two to four months after the triggering event, which explains why most GLP-1 users report shedding at the three-to-six-month mark. The condition is almost always temporary and self-limiting when the underlying stressor resolves.
Evidence: "Rapid and substantial weight reduction can precipitate nutritional deficiencies — particularly of iron, zinc, vitamin D, and biotin — which are recognized triggers for telogen effluvium." — Buontempo F, et al. J Eur Acad Dermatol Venereol. 2025. DOI: 10.1111/jdv.20512
2. Nutritional Deficiencies Secondary to Appetite Suppression
GLP-1 agonists markedly reduce appetite and food intake. If caloric restriction is not paired with adequate micronutrient intake, deficiencies in iron, zinc, biotin, and protein can develop. These nutrients are critical for the hair growth cycle:
- Iron — deficiency is one of the most common reversible causes of hair loss in women
- Zinc — essential for DNA synthesis in rapidly dividing hair follicle cells
- Biotin — a cofactor in keratin synthesis
- Protein — hair is ~95% keratin; inadequate intake directly limits follicle production
3. Direct GLP-1 Receptor Activity in the Hair Follicle
A smaller body of evidence suggests GLP-1 receptors may be expressed on hair follicle cells, raising the possibility that receptor agonism directly influences the follicular cycle. Three studies in the systematic review published in PMC noted significant improvement and hair regrowth in patients using tirzepatide for androgenic alopecia, suggesting the relationship is complex and bidirectional.
Evidence: "Three studies highlighted significant improvement and hair regrowth in affected areas after tirzepatide use, suggesting complex and sometimes divergent effects across different types of alopecia." — Hair Loss Associated With GLP-1 Receptor Agonist Use: A Systematic Review. PMC. PMC12530271
Who Is Most at Risk?
Not every GLP-1 user will experience hair loss, but several factors increase vulnerability:
- Magnitude of weight loss — Losing ≥20% body weight significantly raises risk compared to lesser losses
- Speed of weight loss — Rapid reductions are more likely to trigger TE than gradual ones
- Pre-existing nutritional deficiencies — Low baseline iron or zinc amplifies follicular stress
- Female sex — Women have higher reported rates, likely due to pre-existing hormonal vulnerability
- Personal or family history of androgenic alopecia — GLP-1 use may accelerate underlying genetic hair loss
- Inadequate protein intake during treatment — Especially in people who restrict food heavily
Evidence-Based Strategies to Prevent and Manage Hair Loss
Optimize Nutrition
Maintaining adequate protein intake is the single most actionable step. Clinical nutritionists working with bariatric patients — whose metabolic situation mirrors rapid-weight-loss GLP-1 users — typically recommend 1.2–1.5 g of protein per kg of ideal body weight per day during active weight loss phases.
Routine lab panels should include ferritin, serum zinc, vitamin D (25-OH), and a complete metabolic panel at baseline and every three to six months on therapy.
Avoid Overly Aggressive Calorie Restriction
GLP-1 medications are powerful appetite suppressants. Some users inadvertently consume far too few calories, worsening nutritional depletion. A registered dietitian consultation helps ensure intake remains above the physiological floor needed to sustain hair follicle function (generally ≥1,000–1,200 kcal/day for women, ≥1,200–1,500 for men, with adequate protein).
Consider Targeted Supplementation
If labs reveal deficiencies, targeted repletion — particularly iron supplementation in women with low ferritin — can help resolve TE. Biotin supplementation is widely used but evidence is weak unless a true deficiency is documented. Zinc supplementation at modest doses (8–15 mg/day) may be appropriate if levels are low.
Discuss any supplementation with your prescribing physician, as high-dose biotin can interfere with certain thyroid and cardiac lab assays.
Topical Minoxidil
For cases persisting beyond six months, topical or oral minoxidil may accelerate regrowth. While not GLP-1-specific, minoxidil extends the anagen phase and is supported by extensive evidence for both men and women with diffuse hair loss. A dermatologist can evaluate whether this intervention is appropriate.
Evidence: "Clinicians are advised to include GLP-1 agonists in the medication history of patients presenting with hair loss and to ensure patients maintain adequate nutrition to mitigate the risk of telogen effluvium." — Alopecia and Semaglutide: Connecting the Dots for Patient Safety. PMC. PMC11909624
Will Hair Grow Back?
For the majority of users experiencing telogen effluvium, the answer is yes. TE is a self-limiting condition. Once the physiological stressor (rapid weight loss, nutritional deficit) stabilizes, the hair cycle normalizes and regrowth typically begins within three to six months — although full density may take up to a year to restore.
Cases involving androgenic alopecia that was accelerated by GLP-1 use may follow a different trajectory and warrant early dermatologic evaluation.
Importantly, hair loss alone is not a reason to discontinue GLP-1 therapy for most patients. The metabolic and cardiovascular benefits of these medications — reduced HbA1c, cardiovascular risk reduction, improved sleep apnea — typically outweigh a temporary and manageable side effect. This is a clinical conversation to have with your physician rather than a unilateral decision.
Key Takeaways
- Hair loss affects a meaningful minority of GLP-1 users, most commonly as telogen effluvium triggered by rapid weight loss
- The risk is dose-dependent on weight loss magnitude: losing ≥20% body weight roughly doubles the incidence compared to lesser losses
- Nutritional deficiencies — especially iron, zinc, and protein — are key mediators and are modifiable
- Shedding typically peaks at three to six months and resolves within six to twelve months in most cases
- Optimization of protein intake, monitoring for micronutrient deficiencies, and avoiding overly aggressive calorie restriction are the most evidence-supported prevention strategies
- Patients should disclose GLP-1 use to any dermatologist assessing hair loss, as the medication history changes the differential diagnosis
References
Burke JM, et al. Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. J Am Acad Dermatol. 2025. DOI: 10.1016/j.jaad.2025.01.046 | PubMed
Tran JT, et al. Increased risk of telogen effluvium with tirzepatide compared to other weight loss medications: A retrospective cohort TriNetX database study. J Am Acad Dermatol. 2025. DOI: 10.1016/j.jaad.2025.02659
Buontempo F, et al. Exploring the hair loss risk in glucagon-like peptide-1 agonists: Emerging concerns and clinical implications. J Eur Acad Dermatol Venereol. 2025. DOI: 10.1111/jdv.20512
Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. PubMed Central. 2025. PMC12530271
Alopecia and Semaglutide: Connecting the Dots for Patient Safety. PubMed Central. 2025. PMC11909624
Alopecia as an Emerging Adverse Effect Associated With GLP-1 Receptor Agonists for Weight Loss: A Scoping Review. PubMed Central. 2025. PMC12431796
Last updated: 2026-04-10
Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.